Eisai Files Application Seeking Additional Indication for ARICEPT in Europe.
Tokyo, Japan, May 17, 2006 - (JCN) - Eisai announced on May 16 that its UK subsidiary Eisai Ltd. has filed an application for ARICEPT Ar·i·cept (âr  -s pt (donepezil donepezil /do·nep·e·zil/ (do-nep´e-zil) an acetylcholinesterase inhibitor used as the hydrochloride salt for the treatment of mild to moderate symptoms of dementia of the Alzheimer type; administered orally. HC1 tablet) with the Medicines and Healthcare Products Regulatory Agency of the UK.
The company intends to seek approval in 12 European countries under the Mutual Recognition procedure.
Eisai expects that ARICEPT will become available for the treatment of severe Alzheimer's disease. Currently, about 4.5 million people have Alzheimer's disease in Europe.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion